We focus on the development of novel medicines using our proprietary Extreme Genetics® platform.
We are a clinical-stage biopharmaceutical company discovering and developing a pipeline of differentiated therapeutics for orphan indications that we intend to commercialize on our own, and for larger market indications that we intend to partner with global pharmaceutical industry leaders. We have built a core platform, which we call Extreme Genetics®, enabling the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels, known as channelopathies. Our integrated platform has a full complement of in-house capabilities for human genetics and small molecule drug discovery, and for pre-clinical and clinical development.
December 15, 2014 – Xenon Pharmaceuticals Reports Third Quarter 2014 Financial Results
November 10, 2014 – Xenon Announces Closing of Initial Public Offering and Full Exercises of the Underwriters’ Option to Purchase Additional Shares
November 4, 2014 – Xenon Announces Pricing of Initial Public Offering